Back to search

Article

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

2022-12-13

Abstract excerpt

<h4>SUMMARY</h4> SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programmes, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candidate coded...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b506213e-938c-5462-b021-a4131e9c3ea3
DOI
10.1101/2022.12.13.520255
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primatesDOI 10.1101/2022.12.13.520255
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialSemantic proximity
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialSemantic proximity
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trialSemantic proximity
Humoral Immune Response Against Sars-Cov-2 Variants (Omicron Ba.1, Ba.4/5, Beta and Delta) of Phh-1v Booster Vaccine in Subjects Previously Vaccinated with a Mrna Vaccine. Results of a Randomised Controlled Trial Up to 6 MonthsSemantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
Humoral Immune Response Against XBB.1.5 and BQ.1.1 SARS-COV-2 Variants of a Fourth Dose of PHH-1V Vaccine in Adult Subject: Preliminary Results of HIPRA-HH-2 Extension StudySemantic proximity
SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEARSemantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies: a systematic reviewSemantic proximity
Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaquesSemantic proximity
SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaquesSemantic proximity
A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus MacaquesSemantic proximity
Select a neighboring publication to make it the new centre.